Literature DB >> 35504038

Environmentally Responsible and Cost-Effective Synthesis of the Antimalarial Drug Pyronaridine.

Joseph R A Kincaid1, Rahul D Kavthe1, Juan C Caravez1, Balaram S Takale1, Ruchita R Thakore1, Bruce H Lipshutz1.   

Abstract

Two routes to the antimalarial drug Pyronaridine are described. The first is a linear sequence that includes a two-step, one-pot transformation in an aqueous surfactant medium, leading to an overall yield of 87%. Alternatively, a convergent route utilizes a telescoped three-step sequence involving an initial neat reaction, followed by two steps performed under aqueous micellar catalysis conditions affording Pyronaridine in 95% overall yield. Comparisons to existing literature performed exclusively in organic solvents reveal a 5-fold decrease in environmental impact as measured by E Factors.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35504038      PMCID: PMC9112334          DOI: 10.1021/acs.orglett.2c00944

Source DB:  PubMed          Journal:  Org Lett        ISSN: 1523-7052            Impact factor:   6.072


The antimalarial drug Pyronaridine was developed in the 1970s and 1980s in response to the rise in chloroquine-resistant Plasmodium.[1] In addition to effectively treating malaria, it showed significantly lower toxicity compared to chloroquine,[1b,2] and when administered in combination with other antimalarials such as sulfadoxine and pyrimethamine little-to-no resistance to the drug was observed.[3] Current research into repurposing pyronaridine for the treatment of nonmalarial parasitic diseases,[4] cancer,[5] and bacterial[6] and viral[7] infections has shown promise, including its potential in the ongoing fight against the SARS-CoV-2 virus responsible for the COVID-19 pandemic.[7b] Nonetheless, its primary purpose remains as a treatment for malaria, especially in tropical regions of the world. However, from the perspective of pharmaceutical companies, justifying the sale of drugs to the developing world can be fiscally challenging;[8] hence, the development of a synthetic route which minimizes cost is imperative to incentivize the production of Pyronaridine. Moreover, increasing pressure from governmental restrictions, such as the REACH regulation in the EU,[9] requires chemical manufacturers to reduce their environmental footprint, providing additional incentive for the development of a greener route to Pyronaridine. Fortunately, both aims are achievable by utilizing an environmentally responsible approach that relies on reactions run in Nature’s “solvent”: water.[10] Such a “switch”[11] is enabled using aqueous micellar catalysis, which simply involves the presence of an appropriately engineered and readily available micelle-forming nonionic surfactant that promotes solubilization of typically water-insoluble substrates.[12] Furthermore, use of a common aqueous medium enables telescoping of reactions, thereby eliminating wasteful intermediate workups,[13] while gaining in both time and pot economies.[14] We now describe our recent efforts in collaboration with the Bill and Melinda Gates Foundation that have led to two inexpensive, scalable, and environmentally attractive routes to Pyronaridine.

Overview

Both linear and convergent routes were developed for consideration toward scaling up a synthesis of Pyronaridine (Scheme A and B). Each shares the same initial Cu(I)-catalyzed Ullmann coupling between commercially available 2,4-dichlorobenzoic acid 1 and aminopyridine 2 to arrive at adduct 3, run under aqueous micellar catalysis conditions derived from amphiphile TPGS-750-M[15] (shown in Scheme C). Subsequent cyclization/deoxychlorination to afford the dichlorotricyclic heteroaromatic 4 required the use of especially water-sensitive POCl3 and was, therefore, carried out in recyclable toluene. The linear route continues directly from here via a two-step, one-pot acid-induced SNAr involving 4 and p-aminophenol 5 leading to intermediate 6. Without isolation, 6 undergoes a double Mannich-like reaction. Both reactions take place smoothly in aqueous solution to cleanly afford Pyronaridine (9).
Scheme 1

Overview of Linear and Convergent Routes to Pyronaridine

Alternatively, the convergent route employs a three-step tandem sequence involving an initial double Mannich-like reaction using nitrophenol 10 as educt to install the two required methylpyrrolidine residues to arrive at 11. In this case, the reaction could be performed in the complete absence of any reaction medium (i.e., under neat conditions). Nitro group reduction of 11 to 12 is then readily effected in aqueous surfactant solution. An acid-induced SNAr reaction between 4 and 12 merges both components to afford Pyronaridine, 9.

Ullmann Coupling to Acid 3

The Ullmann reaction between acid 1 and aminopyridine 2 to form 3 was performed in an aqueous solution of 2 wt % TPGS-750-M[15] at a global concentration of 1 M. Purification involved acidification of the aqueous medium to pH 4.0, followed by collection of the precipitated product 3 via filtration. Copper salts were most efficiently removed by centrifugation rather than by suction filtration as the latter approach created a large amount of foam. Unreacted aryl acid 1 could be isolated by further acidification of the filtrate to pH 1, collection by filtration, and recrystallization from EtOH and water. Optimization studies involving the amount of catalytic copper and the role of the surfactant are shown in Table . Increasing the loading of CuI from 5 to 10 mol % led to a moderate increase in yield (entry 2). The importance of the surfactant was also apparent, as in its absence the yield was reduced accordingly (entries 3 and 4); thus, the conditions in entry 2 were selected. Some surfactant remained in the precipitated product, although the yields in entries 1 and 2 do not reflect this. Importantly, the product could be used without further purification and the residual surfactant did not impact the yield or purity of the subsequent cyclization/deoxychlorination step (87% overall yield for both steps, vide infra). It is noteworthy that product 3 was obtained with very high regioselectivity (i.e., no substitution at the para-position was observed by HPLC).
Table 1

Optimization Studies of Ullmann Coupling

entryCuI (mol %)surfactantisolated yield (%)
15TPGS-750-M91
210TPGS-750-M>99
35none; on water73
410none; on water82

Cyclization/Deoxychlorination to Aryl Chloride 4

Cyclization and concomitant deoxychlorination of compound 3 to form heteroaromatic 4 was achieved using POCl3. Et3N was included to prevent evolved HCl from demethylating the methoxy group and leading to impurity I (Figure ) following subsequent deoxychlorination.[16] Although water could not be used in this step due to the water-sensitive nature of POCl3, toluene served nicely and could be recovered following isolation of product 4, thereby limiting organic waste generation. The product was obtained in 87% yield.
Figure 1

Potential impurity I resulting from demethylation.

Potential impurity I resulting from demethylation.

Linear Sequence

SNAr Reaction to Phenol 6

The SNAr reaction between 4 and aminophenol 5 was performed under acidic conditions (pH = 1) and proceeded smoothly using the ideal equimolar quantities of each coupling partner. Product 6 precipitated from the reaction mixture and was obtained in quantitative yield. Following washing with water, the product was obtained in high purity.

Mannich-like Reaction to Form Pyronaridine

Initial screening of the double Mannich-like reaction between 6 and excess (10 equiv) pyrrolidine 7 and paraformaldehyde 8 under micellar catalysis conditions provided Pyronaridine, 9, in quantitative yield. Reducing the loading of pyrrolidine 7 and paraformaldehyde 8 from 10 to 4 equiv led to a precipitous drop in conversion, from 100% to 33%, due to poor solubility of educt 6. That is, the reaction containing 10 equiv pyrrolidine begins as a homogeneous emulsion, and then soon thereafter, Pyronaridine slowly precipitated to form a free-flowing suspension over the course of the reaction. The reaction containing 4 equiv, however, did not afford an initial homogeneous mixture, and instead, amine 6 formed a clump, thereby limiting the extent of conversion. This suggested that the excess pyrrolidine was acting either as a cosolvent, a base, or a combination thereof. The addition of 10 v/v % 2-MeTHF as cosolvent containing 4 equiv of 7 and 8 did not improve the overall conversion. However, use of five equivalents each of 7 and 8 in combination with three equivalents of Et3N showed the same initial solubilization and eventual precipitation of 9. In this manner, Pyronaridine could be isolated in quantitative yield.

Two-Step, One-Pot Conversion of 4 to Pyronaridine

The SNAr followed by the Mannich-like reactions could be performed in water in a one-pot fashion. An initial SNAr reaction between 4 and 5 was performed to afford adduct 6. The reaction mixture was then neutralized with NaHCO3, after which was added 7, 8, and Et3N. Pyronaridine 9 was thereby obtained in quantitative yield over both steps. The overall linear sequence, therefore, is performed in four individual steps in three pots. The overall efficiency has been increased from 43%[16] to 87% using this process.

Convergent Sequence

Mannich-like Reaction to Form Nitroarene 11

The Mannich-like reaction between p-nitrophenol 10, pyrrolidine 7, and paraformaldehyde 8 was performed under neat conditions. Following addition of 10 and 7 to the pot, the exotherm was effectively mitigated by slow portion-wise addition of 8 at 5 °C. Once all of the reagents had been added, the mixture was heated to 100 °C for 4 h. The remaining pyrrolidine was removed by codistillation with methanol, whereupon nitro compound 11 was obtained in quantitative yield. No over- or under-substitution was observed.

Reduction of Nitroarene 11 to Aniline 12

The nitro group reduction could be performed in aqueous surfactant solution using Pd/C and atmospheric hydrogen pressure.[17] It was necessary to include HCl, as the free-base aniline is highly unstable. Because product 12 is water-soluble, isolation from the aqueous solution is not straightforward. Fortunately, it was found that the subsequent SNAr reaction could be performed in a tandem fashion (see sequence below).

SNAr Reaction with 12 Leading to Pyronaridine

The SNAr reaction was performed in 2 wt % aqueous TPGS-750-M under acidic conditions using a 1:1 ratio of coupling partners 4 and 12. Pyronaridine 9 precipitated from the aqueous reaction mixture, and was isolated via centrifugation followed by washing the solid with water leading to the targeted drug in 78% isolated yield. Interestingly, this yield is lower than would be expected from the 3-step tandem sequence in which Pyronaridine is obtained in 95% yield (vide infra). This suggests that in situ formation of the aniline salt, as in the tandem sequence, is preferrable to direct use of the isolated trihydrochloride salt.

Tandem Three-Step Sequence to Pyronaridine

Beginning with nitrophenol 10 and having heteroaromatic 4 in hand (vide supra), both pyrrolomethylene groups were installed to yield intermediate 11. Stripping with methanol removed excess pyrrolidine, to which was then added an aqueous 2 wt % solution of TPGS-750-M. Introduction of HCl and Pd/C under an atmosphere of H2 led to nitro group reduction to give intermediate 12. The Pd/C was then removed via filtration of the reaction mixture through a short plug of Celite. To this filtrate was then added heteroaryl chloride 4, and the mixture was allowed to react at 75 °C for 16 h. Upon completion, the solution was basified to pH 8 with aqueous NH4OH and the precipitated Pyronaridine (9) was collected via filtration, washed with water, and isolated in an overall yield of 95% over three steps. Since Pyronaridine is offered as its tetraphosphate salt, opportunities for further purification exist, although they were not pursued in these studies. The convergent process involves a three-step sequence from educt 10 that avoids isolation of intermediates and proceeds in an overall yield of 95%. Clearly, this approach has significant advantages that include: (1) avoidance of waste-generating organic solvents; (2) both time[14a] and pot[14b] economies, avoiding workup normally associated with each step; (3) the overall efficiency of the process has been increased from the literature value of 69%[18] to 95%.

E Factors

To quantify the reduction in environmental impact relative to a literature protocol,[18] an Environmental Factor (E Factor)[19] was determined, calculated as the ratio of the mass of waste generated to the mass of product. This was evaluated for the three-step tandem sequence leading to Pyronaridine 9, starting with p-nitrophenol 10 (Scheme B). This led to a 5-fold decrease in E Factor to a very low value of 9, exemplifying the environmental friendliness of the described sequence. Overall, some of the major comparisons between an existing literature route[18] and the current, far greener synthesis are summarized in Scheme .
Scheme 2

Comparisons with Existing Route[18]

Summary

Two economically attractive and environmentally responsible approaches to the synthesis of the antimalarial drug Pyronaridine have been disclosed which should reduce the cost barrier to its production for eventual distribution in various regions in the world. The convergent route appears to be the most effective in terms of both “greenness” and overall efficiency, but only by virtue of its scale up, currently underway, will its preferred status be confirmed.
  21 in total

1.  Pharmaceuticals and the developing world.

Authors:  Michael Kremer
Journal:  J Econ Perspect       Date:  2002

2.  [Polychemoresistant Plasmodium falciparum malaria, successfully treated with a benzonaphthyridine].

Authors:  J Lapierre
Journal:  Nouv Presse Med       Date:  1982-02-27

3.  High Turnover Pd/C Catalyst for Nitro Group Reductions in Water. One-Pot Sequences and Syntheses of Pharmaceutical Intermediates.

Authors:  Xiaohan Li; Ruchita R Thakore; Balaram S Takale; Fabrice Gallou; Bruce H Lipshutz
Journal:  Org Lett       Date:  2021-10-06       Impact factor: 6.005

4.  Review of pyronaridine anti-malarial properties and product characteristics.

Authors:  Simon L Croft; Stephan Duparc; Sarah J Arbe-Barnes; J Carl Craft; Chang-Sik Shin; Lawrence Fleckenstein; Isabelle Borghini-Fuhrer; Han-Jong Rim
Journal:  Malar J       Date:  2012-08-09       Impact factor: 2.979

5.  Absence of association between pyronaridine in vitro responses and polymorphisms in genes involved in quinoline resistance in Plasmodium falciparum.

Authors:  Bruno Pradines; Sébastien Briolant; Maud Henry; Claude Oeuvray; Eric Baret; Rémy Amalvict; Eric Didillon; Christophe Rogier
Journal:  Malar J       Date:  2010-11-25       Impact factor: 2.979

6.  Pot economy and one-pot synthesis.

Authors:  Yujiro Hayashi
Journal:  Chem Sci       Date:  2016-01-06       Impact factor: 9.825

7.  The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase.

Authors:  Giorgia Mori; Beatrice Silvia Orena; Clara Franch; Lesley A Mitchenall; Adwait Anand Godbole; Liliana Rodrigues; Clara Aguilar-Pérez; Júlia Zemanová; Stanislav Huszár; Martin Forbak; Thomas R Lane; Mohamad Sabbah; Nathalie Deboosere; Rosangela Frita; Alexandre Vandeputte; Eik Hoffmann; Riccardo Russo; Nancy Connell; Courtney Veilleux; Rajiv K Jha; Pradeep Kumar; Joel S Freundlich; Priscille Brodin; Jose Antonio Aínsa; Valakunja Nagaraja; Anthony Maxwell; Katarína Mikušová; Maria Rosalia Pasca; Sean Ekins
Journal:  Tuberculosis (Edinb)       Date:  2018-08-11       Impact factor: 3.131

8.  Preclinical Antimalarial Combination Study of M5717, a Plasmodium falciparum Elongation Factor 2 Inhibitor, and Pyronaridine, a Hemozoin Formation Inhibitor.

Authors:  Matthias Rottmann; Brian Jonat; Christin Gumpp; Satish K Dhingra; Marla J Giddins; Xiaoyan Yin; Lassina Badolo; Beatrice Greco; David A Fidock; Claude Oeuvray; Thomas Spangenberg
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

9.  Repurposing the antimalarial pyronaridine tetraphosphate to protect against Ebola virus infection.

Authors:  Thomas R Lane; Christopher Massey; Jason E Comer; Manu Anantpadma; Joel S Freundlich; Robert A Davey; Peter B Madrid; Sean Ekins
Journal:  PLoS Negl Trop Dis       Date:  2019-11-21

10.  Repurposing Antimalarials to Tackle the COVID-19 Pandemic.

Authors:  Sanjeev Krishna; Yolanda Augustin; Jigang Wang; Chengchao Xu; Henry M Staines; Hans Platteeuw; Adeeba Kamarulzaman; Amadou Sall; Peter Kremsner
Journal:  Trends Parasitol       Date:  2020-10-19
View more
  1 in total

Review 1.  Cascade Processes with Micellar Reaction Media: Recent Advances and Future Directions.

Authors:  Christina Tang; Bridget T McInnes
Journal:  Molecules       Date:  2022-08-31       Impact factor: 4.927

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.